Introduction {#Sec1}
============

Severe pain has profound physiologic effects on the endocrine system \[[@CR1]--[@CR12]\]. Fundamentally, severe pain, whether it be acute or chronic, is a severe stressor that activates the hypothalamic--pituitary--adrenal--thyroid--gonadal (HPATG) system, which is the major stress control mechanism of the body \[[@CR10], [@CR13]--[@CR16]\]. This system is often referred to as an 'axis' since it is a closed system with hormonal feedback or controls within the system \[[@CR16]--[@CR18]\]. This paper will refer to the 'axis' as the HPATG system. The biologic purpose of this system (see Fig. [1](#Fig1){ref-type="fig"}) is to produce additional hormones in the thyroid, adrenals and gonads, and secrete them into the serum as these compounds are required by the body for many pain-control functions, including protection and regeneration of injured tissue, immunologic activity, and metabolic controls \[[@CR13], [@CR16], [@CR17]\]. Once these extra hormones, such as thyroid, cortisol, or testosterone, enter the serum, they travel throughout the body to target areas, including injured nerves and the central nervous system (CNS) \[[@CR18], [@CR19]\]. Although it is known that pain has an effect on neurohormones produced in the brain, insulin produced in the pancreas, and adrenalin produced in the adrenal medulla, there are few studies or reports on these effects \[[@CR1]--[@CR5]\], and they will not be covered here. Over the past 50 years, however, there have been numerous reports and studies on pain's physiologic effect on the HPATG system, so this is the focus of this paper \[[@CR1]--[@CR12], [@CR20]--[@CR30]\]. It is also cogent to note that the accumulated information and understanding about the effects of pain on the HPATG system is now such that testing and replacement of certain hormones should be a basic foundation of clinical pain treatment.Fig. 1Pain stimulation of the hormone system causes adrenal, gonad and thyroid hormone levels to elevate in the serum. If pain remains uncontrolled for a considerable time period, hormonal depletion may occur, and serum levels drop below normal

Hormone Functions in Pain Control {#Sec2}
=================================

Adequate pain control may not be achieved without homeostasis of certain hormones \[[@CR31]--[@CR52]\]. Hormonal homeostasis is defined here as the maintenance of a hormone within a normal serum range. The critical pain-control hormones that are produced in glands outside the CNS are cortisol, pregnenolone, dehydroepiandrosterone (DHEA), progesterone, testosterone, estrogen, and thyroid (Table [1](#Tab1){ref-type="table"}) \[[@CR31]--[@CR52]\]. Among the primary pain-control functions of these hormones are immune and anti-inflammatory actions, cellular protection, tissue regeneration, glucose control, and modulation of CNS receptors, the blood--brain barrier, and nerve conduction (Table [2](#Tab2){ref-type="table"}) \[[@CR53]--[@CR63]\]. Given the CNS effects of certain hormones, analgesics such as anti-depressants, neuropathic agents and opioids, may not achieve maximal analgesic responses without hormone homeostasis \[[@CR19], [@CR33], [@CR37], [@CR42], [@CR49]--[@CR53]\].Table 1Hormones from peripheral glands that are critical for pain controlHormone Cortisol Dehydroepiandrosterone Estrogen Pregnenolone Progesterone Testosterone ThyroidTable 2Major pain-control mechanisms of hormonesPain-control mechanism Anti-inflammatory action Cellular metabolism Cellular protection Glucose control Immunoreactivity Tissue regeneration Central nervous system functions  Receptor binding  Nerve conduction  Maintenance of blood--brain barrier

The Releasing Hormones {#Sec3}
----------------------

Pain signals that reach the brain from any injury in the peripheral nervous system activate three releasing hormones in the hypothalamus (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR9], [@CR15], [@CR48]\]. These are corticotropin releasing hormone (CRH), gonadal releasing hormone (GRH), and thyroid releasing hormone (TRH) \[[@CR8], [@CR9], [@CR12], [@CR48]\]. These three hormones, in turn, cause the anterior pituitary to release into serum adrenal corticotropin hormone (ACTH), follicle stimulating hormone (FSH), luteinizing hormone (LH), and thyroid stimulating hormone (TSH). The end organs for stimulation are the adrenals, gonads, and thyroid, which release into the serum hormones necessary for pain control including cortisol, pregnenolone, DHEA, testosterone, progesterone, estrogen, triiodothyronine (T~3~), and thyroxine (T~4~) (Table [1](#Tab1){ref-type="table"}). Adrenalin and other catecholamines are also released from the adrenal medulla, but it is only partially a result of ACTH stimulation. Serum concentrations of the pituitary and end-organ hormones can now be assayed in commercial laboratories and replacement hormones are also readily available. Consequently, the old saying that pain, "cannot be measured" needs to be modified. Serum levels of the pituitary and end-organ hormones noted here serve as biomarkers for uncontrolled pain (see Table [3](#Tab3){ref-type="table"}) \[[@CR3], [@CR7], [@CR30], [@CR64]\]. In other words, it may not be possible to quantitate pain per se, but it is now possible to determine whether pain severity has reached a level that activates the HPATG system \[[@CR29], [@CR64]\]. It should be noted that commercial assays for the hypothalamic-releasing hormones (CRH, GRH, TRH) are in the developmental stages, and when available, will provide an even more direct assessment of brain overstimulation because of pain \[[@CR48]\].Table 3Clinical features of Cushing's Syndrome and the proportion of patients affected by these featuresClinical featureProportion of patients affected (%)Obesity or weight gain95Facial plethora90Decreased libido90Rounded face90Thin skin85Menstrual irregularity80Hypertension75Hirsutism75Depression70Bruise easily65Glucose intolerance60Weakness60Osteopenia/fracture/dental erosion50Nephrolithiasis50Adapted from Newell-Price et al. \[[@CR84]\]

The Stimulation Phase {#Sec4}
---------------------

It is important to note that only severe pain will stimulate HPATG to the point that the end organs produce and secrete sufficient hormones to raise serum levels above normal (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR29], [@CR65]\]. Studies show that patients with mild or intermittent pain, such as in common degenerative arthritis, have normal hormone serum levels \[[@CR65]\]. This is an excellent practical point for the pain practitioner, since normal serum hormone levels usually mean that the patient's pain is not in need of therapy with high-risk treatment, such as long-acting opioid drugs or invasive interventions \[[@CR66]--[@CR74]\]. Put another way, hormone serum levels are excellent biomarkers that help separate severe from mild pain. If end-organ serum hormone levels are above normal, however, enhanced pain-control treatment will be needed \[[@CR75]\]. If hormones are below normal levels, it is prudent to replace the hormones and achieve homeostasis before embarking on a therapeutic regimen that has risks, such as opioid-induced endocrine suppression \[[@CR23], [@CR66]--[@CR74]\].

The Depletion Phase {#Sec5}
-------------------

If tissues in the hypothalamus, pituitary, adrenals, gonads, or thyroid cannot sustain the demands of severe pain, serum levels of some hormones may drop below normal levels \[[@CR10], [@CR29], [@CR64]\]. Based on the clinical experience to date, the most common end-organ hormones to diminish in the serum due to uncontrolled pain are cortisol, pregnenolone, DHEA, and testosterone \[[@CR29], [@CR30], [@CR75]\]. It is noted that thyroid depletion occurs, but is quite uncommon according to today's testing technology \[[@CR21]\]. Also, some clinicians believe that thyroid depletion should be assessed according to the symptoms rather than current assays for T~3~ and T~4~ \[[@CR26]\]. Once pain is controlled and/or hormones are replaced, serum levels will almost always return to normal. It should be emphasized that only severe pain will stimulate HPATG to the point that the end organs will not produce sufficient hormones to maintain homeostasis \[[@CR65]\].

Cortisol Abnormalities: The Most Serious Hormone Complications {#Sec6}
==============================================================

Chronic cortisol abnormalities, when levels are either too high or too low, over an extended time period are the major hormonal problems in chronic pain patients. Although the prevalence of cortisol abnormalities in chronic pain patients is unknown, excess and deficient cortisol states are starting to be recognized among pain patients \[[@CR7], [@CR10], [@CR29]\]. Extended periods of exposure to excess cortisol, often referred to as Cushing's Syndrome, named after Harvey Cushing who first described the clinical signs and symptoms in patients with pituitary tumors, has serious complications \[[@CR76]--[@CR82]\]. Complications include osteoporosis, hypertension, hyperlipidemia, and mental deficiencies (Table [3](#Tab3){ref-type="table"}). Until now, many of these complications in pain patients were simply viewed as unrelated, random events. Table [3](#Tab3){ref-type="table"} lists the complications of hypercortisolemia \[[@CR84]\]. The major complications that manifest in pain patients are osteoporosis, joint degeneration, tooth decay, hypertension, hyperlipidemia, obesity, and mental deterioration \[[@CR76]--[@CR82]\]. Although the hypercortisol complications listed here are well known, the pain patient may decondition themselves to adequately move or exercise. Consequently, multiple reasons for these complications may develop.

The disease originally described by Cushing was due to pituitary adenomas, which we now know is caused by the constant secretion of ACTH by the pituitary, which raises serum cortisol levels \[[@CR76]--[@CR78], [@CR82]\]. In chronic pain patients, hypercortisolemia is usually episodic and only occurs during flares or periods of undertreatment that force the hypothalamus and pituitary to temporarily secrete ACTH and cortisol. Physiologically, however, it makes little difference whether high serum cortisol levels are intermittent or constant, because chronic pain patients may experience high cortisol levels, even if intermittent, over long time periods and develop sustained complications. It is very likely that joint degeneration, renal stones, vertebral collapse, hypertension, dementia, and hyperlipidemia so commonly observed in chronic pain patients are the results of intermittent hypercortisolemia over an extended period of time. Of particular concern is that hypercortisolemia causes calcium resorption, which is the apparent cause of osteoporosis, dental erosion, joint degeneration, nephrolithiasis (renal stones) and vertebral collapse. The problem of calcium resorption in pain patients may be compounded by poor diet, a lack of dietary supplements, and immobilization due to pain \[[@CR29], [@CR76], [@CR78], [@CR80], [@CR81]\]. Pain practitioners must be alert and recognize these complications and evaluate patients for cortisol abnormalities.

Long-term hypocortisolemia, often known as Addison's Disease, has a different set of complications. Hypocortisolemia produces weight loss, muscle wasting, mental apathy, hypotension, and, if not detected and treated, it may cause sudden death. In patients who take opioids, testosterone is the major hormone suppressed, although opioids may also suppress cortisol. It is not known the precise opioid dosage or time frame necessary for suppression of testosterone and/or cortisol to occur. However, it is known that long-acting opioids and a longer duration of opioid treatment play a role \[[@CR74]\]. The author has observed that suppression may occur within 90 days after a patient initiates opioid use.

Adrenal insufficiency was first described by Thomas Addison in 1855 \[[@CR83]\]. Serum testing and even the name cortisol were not yet conceived at the time. Thomas Addison's treatise was called, "On the Constitutional and Local Effect of Disease of the Supra-Renal Capsules." He reported on 11 patients who died from severe disease of the supra-renal capsules (now called the adrenal glands), and who had a similar clinical history of weight loss, muscle wasting, lowered blood pressure, decreased mental ability, yellowish hue to the skin, and pigmentation around scars, gums, axillae, and skin creases \[[@CR83]\]. Interestingly, two of his 11 cases had severe pain. One had facial pain and the other had extremity neuropathy. Severe, chronic pain may cause significant cortisol suppression, and a typical Addison's clinical profile will ensue (Table [4](#Tab4){ref-type="table"}). Pain practitioners should suspect this condition if such symptoms as weight loss, muscle wasting, hypotension, and brown pigmentation on the skin are present. Unfortunately, several conditions in pain patients may produce a physical profile similar to Addison's disease. These include immobility, inadequate diet, depression, fatigue, sleep deprivation, malabsorption, autoimmune phenomenon, and malignancy. Only serum cortisol testing can reliably distinguish adrenal insufficiency from these other unfortunate ramifications of severe, chronic pain. Hydrocortisone replacement in hypocortisolemia, as well as enhanced pain control, is essential. It can even be a simple life-saving endeavor (see Table [4](#Tab4){ref-type="table"}) \[[@CR71], [@CR75], [@CR84]\].Table 4Common features of hypocortisolemia in pain patientsFeature Weakness Weight loss Muscle wasting Anorexia Hypotension Mental apathy Tachycardia Yellowish hue to the skin Pigmentation around skin creases or scarsFeatures were reported in Addison's original 1855 \[[@CR85]\] description of patients who died of adrenal failure

Serum Testing and Replacement {#Sec7}
=============================

Due to the two phases, stimulation and depletion, of pain's effect on the HPATG system, practitioners should be prepared for either too high or too low serum hormone levels when they are assayed. Table [5](#Tab5){ref-type="table"} shows a series of serum cortisol levels in 40 intractable pain patients referred to the Veract Intractable Pain Clinic. Note that some are high, some low, and some are normal. In particular, it should be noted that one individual had a cortisol concentration of less than 1.0 μg/dL. This is clearly a dangerous sign, as it indicates that the patient's adrenals are nearly non-functional \[[@CR81]\]. Death may suddenly occur in this situation. I would regard a cortisol level of less than 1.0 μg/dL to be a life-threatening emergency that requires immediate hormone replacement with hydrocortisone.Table 5Mean serum cortisol concentrations in 40 consecutive patients admitted for treatment to the Veract Intractable Pain ClinicPatient no.Serum cortisol concentration (μg/dL)Patient no.Serum cortisol concentration (μg/dL)Patient no.Serum cortisol concentration (μg/dL)Patient no.Serum cortisol concentration (μg/dL)11.11128.9216.2314.724.91211.6224.03216.232.21324.1234.3334.342.2143.92430.13429.8513.01528.9251.33522.7628.51632.52616.13625.87^a^0.61729.02718.53718.784.31827.3289.6389.093.71919.2293.43921.8105.0208.63010.84019.8Patients were referred, undertreated and claimed their pain to be disabling and constant. Note that levels were above and below the normal range, indicating uncontrolled pain. Overall mean (standard deviation, SD) cortisol level among the 40 patients: 13.9 μg/dL (10.3). Mean (SD) cortisol level among those (*n* = 12) with high (\>20 μg/dL) concentration: 27.5 μg/dL (10.8). Mean (SD) cortisol level among those (*n* = 14) with low (\<5 μg/dL) concentration: 3.2 μg/dL (1.4)^a^Patient had such a low level that adrenal failure and death could occur without immediate hydrocortisone replacement

Replacement or partial replacement of hydrocortisone, pregnenolone, DHEA, or testosterone is rightfully emerging as a new procedure in pain treatment \[[@CR75], [@CR81]\]. The benefits appear numerous. In early reports, less medication, particularly opioids, is required if hormone serum levels are normal prior to their initiation \[[@CR77]\]. The author highly recommends that hormone testing and necessary replacement can be done before long-acting opioids and other high-risk measures are instituted.

Opioid Suppression of Hormones {#Sec8}
==============================

Opioids, particularly those that are long-acting or delivered by the intrathecal route, may suppress some hormone production \[[@CR66]--[@CR74]\]. Precise opioid dosages that may produce suppression have not been---and probably cannot be---determined due to individual biologic differences \[[@CR60], [@CR70]\]. It is the constancy of sustained-action opioids, however, that produces a 24-h blood and brain concentration that does not allow the HPATG to produce its usual, normal output of hormones \[[@CR63], [@CR68], [@CR69], [@CR76]\]. Suppressed levels of testosterone are the most common problem with opioid administration, but cortisol, pregnenolone, and DHEA may also be suppressed \[[@CR67], [@CR70]\]. For reasons that are unclear, the thyroid hormones, T~3~ and T~4~, are seldom suppressed \[[@CR25], [@CR70]\]. The predilection for testosterone suppression is believed to be due to the tendency of opioids to preferentially suppress GRH \[[@CR72]\]. Testosterone suppression with long-acting and intrathecal opioids occurs in 75--85 % of patients \[[@CR66], [@CR70], [@CR72], [@CR74]\]. Suppression may begin in the first 90 days of opioid administration and testosterone may remain suppressed as long as opioids are administered. Given this extremely high prevalence, patients who take long-acting opioids need to be regularly screened for testosterone, as well as pregnenolone, DHEA, and cortisol. Replacement of these hormones should be done, as low serum levels of any of these hormones may be associated with poor pain control, including symptoms of allodynia and hyperalgesia \[[@CR84], [@CR85]\]. It is known that central sensitization and neuroinflammation due to glial cell activation are responsible for allodynia and hyperalgesia. Some hormones, particularly the glucocorticoids and sex hormones, have profound immune effects on the CNS \[[@CR39], [@CR41], [@CR49], [@CR54]\]. Hormone replacement has been reported to relieve allodynia and hyperalgesia in some patients \[[@CR75], [@CR84]\]. In a patient who takes opioids, a low serum hormone concentration may be due to opioids, pain, or both. Consequently, in clinical practice, hormone replacement may have to be performed without knowing precisely which mechanism is primarily responsible for hormone deficiencies.

Conclusion {#Sec9}
==========

The basic physiologic effect of pain on the endocrine system is one of severe stress. Pain initially stimulates the HPATG system to produce and secrete extra hormones from the adrenals, gonads, and thyroid. Hormones, including cortisol, pregnenolone, DHEA, testosterone, and thyroid (T~3~ and T~4~) travel from their producing glands to distinct tissue targets, including injured nerves and the CNS. Hormones provide immunologic, anti-inflammatory, and regenerative properties for cellular protection and healing. In the stimulation phase of severe pain, serum hormone levels are elevated. If pain persists unabated for too long, the hormonal system is unable to tolerate the stress of pain, and hormone production may be decreased causing serum hormone levels to drop below normal.

The most serious hormone complications of severe chronic pain are hyper- and hypocortisolemia. Cortisol serum levels rise and fall with emotion, exercise, nutrition, and disease states. Exercise is well known to positively modify cortisol levels, and this activity is highly recommended in pain patients. Chronic hypercortisolemia has numerous complications related to increased calcium resorption and includes osteopenia, joint degeneration, tooth decay, degenerative arthritis, vertebral collapse, and renal stones. Hypocortisolemia may occur in severe, under-treated pain, and cortisol levels may drop below 1.0 μg/dL, which may be too low to sustain life. Low serum cortisol levels are clinically manifested by weight loss, muscle wasting, weakness, hypotension, and pigmentation around scars and skin creases.

Hormone serum levels serve as biomarkers for uncontrolled pain. Before embarking on therapy with long-acting opioids and other pain treatment modalities that carry risks, a minimal hormone assessment should be made to determine whether a chronic pain patient has normal serum levels of cortisol, pregnenolone, DHEA, and testosterone. Early clinical experience indicates that the use of opioids, and possibly other pharmaceutical agents, can be minimized if hormone homeostasis is achieved prior to introduction of these agents. It is cautioned, however, that the patient's report of pain and need for analgesic medication be paramount, and that hormone serum levels should never be the determinant of proper analgesia.
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